Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

VELIPARIB for Colorectal cancer metastatic: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 14 adverse event reports in the FDA FAERS database where VELIPARIB was used for Colorectal cancer metastatic.

Most Reported Side Effects for VELIPARIB

Side Effect Reports % Deaths Hosp.
Neutrophil count decreased 124 31.7% 7 67
Anaemia 118 30.2% 6 63
White blood cell count decreased 94 24.0% 6 53
Febrile neutropenia 76 19.4% 0 69
Platelet count decreased 70 17.9% 6 37
Hypertension 57 14.6% 3 33
Nausea 46 11.8% 2 38
Hyponatraemia 38 9.7% 4 22
Vomiting 36 9.2% 1 30
Hypokalaemia 31 7.9% 3 25
Dehydration 29 7.4% 4 25
Abdominal pain 24 6.1% 1 23
Diarrhoea 23 5.9% 1 20
Fatigue 23 5.9% 0 16
Embolism 19 4.9% 1 13

Other Indications for VELIPARIB

Ovarian epithelial cancer (97) Triple negative breast cancer (67) Colorectal cancer (39) Breast cancer (24) Fallopian tube cancer (21) Ovarian cancer (16) Malignant peritoneal neoplasm (11) Neoplasm (9) Breast cancer metastatic (8) Cervix carcinoma recurrent (8)

Other Drugs Used for Colorectal cancer metastatic

FLUOROURACIL (6,189) BEVACIZUMAB (5,474) IRINOTECAN (4,655) OXALIPLATIN (4,638) LEUCOVORIN (4,624) PANITUMUMAB (3,420) CETUXIMAB (1,960) CAPECITABINE (1,759) TIPIRACIL\TRIFLURIDINE (1,320) REGORAFENIB (1,234)

Related Pages

VELIPARIB Full Profile All Colorectal cancer metastatic Drugs VELIPARIB Demographics VELIPARIB Timeline